United Therapeutics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
United Therapeutics (UTHR) Misses Q4 EPS by $2.05, Misses on Revenue
February 22, 2023 6:06 AM ESTUnited Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $2.67, $2.05 worse than the analyst estimate of $4.72. Revenue for the quarter came in at $491.5 million versus the consensus estimate of $519.21 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
... More